{
  "docId": "019de075-ab2a-73e5-980a-7d480707ba09",
  "docSlug": "340a1966b9939070959283ec1665bfbf",
  "documentTitle": "Kymera | Investor Presentation Deck | 60 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 47,
  "pageCount": 60,
  "prevPage": 46,
  "nextPage": 48,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 24,
  "notes": "Includes a line chart showing % change over time and a summary table of patient-level degradation data.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-ab2a-73e5-980a-7d480707ba09/47",
  "deckHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09",
  "deckJsonHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09.json",
  "deckAnchorHref": "/decks/019de075-ab2a-73e5-980a-7d480707ba09#slide-47",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "chart",
      "text": "Line chart showing % change from C1D1 Predose over days in study for DL1, DL2, and DL3.",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "68da7fd3-9cb4-4885-a9e7-f98a583937c7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.86,
        "x": 0.07,
        "y": 0.68
      },
      "kind": "list",
      "text": "Dose-dependent STAT3 degradation; Mean maximum degradation of up to 85.4% in Cycle 1 and 88.4% in Cycle 2; Weekly maximum reductions of up to 90-91%; Profile at or nearing STAT3 degradation that has been shown to lead to strong antitumor effects",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "364b6213-dcf8-4162-b727-c9e2c48d3b94",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.2,
        "x": 0.8,
        "y": 0.92
      },
      "kind": "subtitle",
      "text": "As of the data cut-off date of May 1, 2023.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c5d63918-fd81-462d-a943-8e417a16dcb5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.45,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "table",
      "text": "Table showing patient ID, dose level, and degradation percentages for Cycle 1 and Cycle 2.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d5333e7-ac83-4a10-8747-08ff92955747",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Strong Proof-of-mechanism for KT-333 with up to 88% Mean Maximum Nearing Desired Degradation Profile at DL3",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3935784e-1995-45ac-8a8c-671158ba5ede",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chartjunk Elimination",
      "slug": "chartjunk-elimination",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "60db86f7-554b-4747-acb8-9adf03ec8445",
      "evidence": "The line chart and table/data presentation are clear and concise, eliminating unnecessary visual clutter.",
      "confidence": 0.8
    },
    {
      "name": "Data Story Arc",
      "slug": "data-story-arc",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "6e112dc5-3fe5-4a63-a050-f4bb251098ca",
      "evidence": "The slide presents a clear narrative arc, showcasing the progression of KT-333's proof-of-mechanism and its effects on STAT3 degradation.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 49,
      "from": 42,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "0814ecd6-3302-463c-8283-d9c36bf778b3",
      "evidence": "The deck presents the why, what, and how of STAT3 as a target",
      "position": 2,
      "objective": "Why is STAT3 a good target for oncology?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}